Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F.

BMC Cancer. 2011 Jan 18;11:21. doi: 10.1186/1471-2407-11-21.

2.

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.

Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC.

Blood. 2011 Feb 10;117(6):1888-98. doi: 10.1182/blood-2010-10-310599. Epub 2010 Dec 1.

3.

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW.

Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.

4.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

5.

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.

Blood. 2010 Nov 11;116(19):3875-86. doi: 10.1182/blood-2010-01-265041. Epub 2010 Jul 14.

6.

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M.

J Biomed Biotechnol. 2010;2010:956304. doi: 10.1155/2010/956304. Epub 2010 May 5. Review.

7.

Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.

Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, Barfield RC, Ming Yu H, Yu AL.

Pain. 2010 Apr;149(1):135-42. doi: 10.1016/j.pain.2010.01.024. Epub 2010 Feb 19.

8.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.

9.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Review.

PMID:
19327974
10.
11.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK.

Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.

12.

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.

Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, Maher J.

J Immunol. 2008 Apr 1;180(7):4901-9.

13.

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR.

J Clin Invest. 2008 Jan;118(1):294-305.

14.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S.

Cancer Res. 2007 Jun 15;67(12):5957-64.

15.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G.

Blood. 2007 Oct 1;110(7):2620-30. Epub 2007 May 16.

16.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.

Clin Cancer Res. 2007 Mar 15;13(6):1857-67.

17.

Improving T cell therapy for cancer.

Leen AM, Rooney CM, Foster AE.

Annu Rev Immunol. 2007;25:243-65. Review.

PMID:
17129181
18.

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group.

Clin Cancer Res. 2006 Mar 15;12(6):1750-9.

19.

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.

Rossig C, Bär A, Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Jürgens H, Vormoor J.

J Immunother. 2006 Jan-Feb;29(1):21-31.

PMID:
16365597
20.

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK.

Mol Ther. 2005 Nov;12(5):933-41. Epub 2005 Jun 23.

Supplemental Content

Support Center